about
Veterinary Medicine Needs New Green Antimicrobial DrugsImpact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations.Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration.Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo EfficaciesBioavailability and its assessment.Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infectionImpact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection modelIn vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations.Species differences in pharmacokinetics and pharmacodynamics.The consequences of generic marketing on antibiotic consumption and the spread of microbial resistance: the need for new antibiotics.Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal floraInfection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.Dominant plasmids carrying extended spectrum β-lactamases blaCTX-M genes in genetically diverse Escherichia coli from slaughterhouse and urban wastewaters.Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms.Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes.Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: comparison of bactericidal activity at the gut versus the systemic level in a pig model.Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.Interpreting bisphenol a absorption in the canine oral cavity: Gayrard et al. Respond.Comment on "In Vitro Effects of Bisphenol A β-D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytes".Persistence and prevalence of pathogenic and extended-spectrum beta-lactamase-producing Escherichia coli in municipal wastewater treatment plant receiving slaughterhouse wastewater.A nonlabeled method to evaluate cortisol production rate by modeling plasma CBG-free cortisol disposition.Intestinal secretion is a major route for parent ivermectin elimination in the rat.Effects of altered plasma alpha1-acid glycoprotein levels on pharmacokinetics of some basic antibiotics in pigs: simulation analysis.Pharmacokinetics of marbofloxacin in horses.Modelling the loss of metabolic capacities of cultured hepatocytes: application to measurement of Michaelis-Menten kinetic parameters in in vitro systems.Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin.Population pharmacokinetics of marbofloxacin in horses: preliminary analysis.Allometric scaling for predicting human clearance of bisphenol A.Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs.Prediction of human prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semi-physiological toxicokinetic model.Comparison of the reduction in the antibacterial potency of a fluoroquinolone conferred by a single mutation in the quinolone resistance-determining region or by the inoculum size effect.En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.Mixing of Shiga toxin-producing and enteropathogenic Escherichia coli in a wastewater treatment plant receiving city and slaughterhouse wastewater.Capacity limits of asialoglycoprotein receptor-mediated liver targeting.Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.A pharmacokinetic model to document the actual disposition of topical ivermectin in cattle.Licking behaviour induces partial anthelmintic efficacy of ivermectin pour-on formulation in untreated cattle.Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A.Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
P50
Q26740600-FE1BCFBA-996D-4D08-B89E-50265B506D51Q31153949-5AB4A136-EF5F-41F1-A2A2-B33B8777C368Q34877042-7EA4DDDC-85BE-45C9-A3AE-24417CE48464Q35823020-FF8B42F6-ECF4-4E67-9827-379EE2FFA2D9Q35985413-0D9C1B4B-B2B5-44BF-A3D8-1B0BEF8E984DQ36401623-11202119-61E1-4EFA-BC88-D90F8B5C9510Q36637193-FBAC2FFF-AB43-4724-8AE0-853CB58BFA61Q37274635-32D112CF-9089-457F-8C9F-DDEA3BE3FC96Q37523457-19D89D81-7245-4346-852E-7C5D95DD2097Q37702887-8A17C033-4BD4-4193-BEDC-2772DE4A197FQ38109929-5A484C12-B046-42DA-922C-20AE570F0928Q38324219-3E11C998-3D57-4293-837D-20E8C46F0074Q40106417-96B46BE6-166D-4B7E-91F5-08FAF50C4EDAQ40388695-56D15113-0C39-4F29-AD02-7E52252C0FD0Q40572997-8D4AE63C-F470-44AF-A39E-46D1FAAE1B5EQ40949236-F9A82CF4-A640-48E6-862B-FA889DB93E5BQ42248243-9A2BC99F-ABDE-480C-AFF4-B69F4AE37FD4Q42612081-69F26499-1E6E-4C4F-8204-EB898476D6DFQ42837024-7A8CA3A3-CA91-4604-967A-50BC85AAF5FCQ43141847-6B9356FD-91C6-44D1-8B01-78A7567700B4Q43360031-EAA1C132-FB6D-418B-8A25-E8D7B873B1E7Q43762932-0F02B099-71DC-41D2-B035-9AF7EBCE3912Q43999012-4B16F9FF-07E4-45FC-AA5E-8919B7937A77Q44039692-0627E0D5-DB44-4AC5-852E-06BE2C40F590Q44063533-0BC2C737-D35B-43F7-8BFF-C270089C1E5CQ44206802-756F7090-3652-417A-B15A-4227ED393ED7Q45112613-776C39F9-1C2C-4499-B50F-6AEA05E8B272Q45120768-C63530F5-488C-48E1-99C4-49FE261014CAQ46761538-528E7E78-886D-4399-B725-90400BA53D4EQ46940052-91D8765B-9118-4EDD-8CCC-3C94FB01A375Q47168396-7725A357-AFE7-4BF3-B28E-4304C543E0E3Q47422990-0335D6C9-695B-4D2B-BA0E-E08CAB3F8840Q49429759-E06C7F3D-EF15-4A00-A54F-41BEE4A947D9Q50145252-63D8AEF2-E9AD-4A93-B111-C4274EC40BBEQ50216455-56C041EF-B484-4185-800F-D0CD208326EAQ52595189-B324AF59-CB22-4A14-B7A8-ABBDC1FC793DQ52610031-96E78FC8-D4ED-4061-8D6E-6BD467DCDBB8Q52713825-758B1406-71FD-4D7D-811A-2019925257A4Q53288013-73A9EAB8-D2C5-45A0-9311-0D1CE14A8795Q57816952-5B70BE25-D12E-4597-936F-3942FAC2C020
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7661-4311
@en
name
Alain Bousquet-Mélou
@ast
Alain Bousquet-Mélou
@en
Alain Bousquet-Mélou
@nl
type
label
Alain Bousquet-Mélou
@ast
Alain Bousquet-Mélou
@en
Alain Bousquet-Mélou
@nl
prefLabel
Alain Bousquet-Mélou
@ast
Alain Bousquet-Mélou
@en
Alain Bousquet-Mélou
@nl
P214
P106
P214
P31
P496
0000-0002-7661-4311
P735
P7859
viaf-219296293